Our People
JHU -Tufts TIC
BIOS
BIOS
Clinical Trial Coordinating Center
Our Training
Read More
Expertise

About BIOS

The Johns Hopkins Brain Injury OutcomeS (BIOS) Division is a clinical trial coordinating center (data management center, imaging reading center, and enrollment center) within the Johns Hopkins School of Medicine Department of Neurology. Its focus is to provide multicenter management to clinical trials evaluating therapeutic, preventive and diagnostic interventions. Led by Dr. Daniel F. Hanley, BIOS has unique expertise in the coordination and management of trials investigating rare neurologic disorders, acute neurologic ICU conditions, rehabilitation, and functional outcomes. Since the 1990s, BIOS has coordinated international, federally funded and industry-sponsored trials across a wide range of conditions for investigators within the JHU departments of Neurology, Neurosurgery, Anesthesiology/Critical Care Medicine, Hematology and Neuroradiology, as well as for investigators at other academic centers around the U.S.

 Read More

Johns Hopkins-Tufts TIC

BIOS and the Johns Hopkins Institute for Clinical and Translational Research (ICTR) have been awarded a seven-year, $25 million grant from the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) to form, along with Tufts University School of Medicine, one of three Trial Innovation Centers (TICs).

The goal of the centers is to promote innovations in the efficiency and quality of NIH-funded trials. The centers are part of the NCATS Trial Innovation Network and will work with the national Clinical and Translational Science Program, which funds a consortium of 64 medical research institutions in 31 states and the District of Columbia. The centers will help the institutions form a long-standing infrastructure for multicenter studies to be funded by NIH and other funding agencies.

 Read More

Recent Publications

Neurocrit Care. 2018 Jan 2
The Incidence of Catheter Tract Hemorrhage and Catheter Placement Accuracy in the CLEAR III Trial
Müller A, Mould WA, Freeman WD2, McBee N, Lane K, Dlugash R, Thompson R, Nekoovaght-Tak S, Madan V1, Ali H, Stadnik A, Awad I, Hanley D, Ziai WC; CLEAR investigators.

Read Article

Int J Stroke. 2018 Jan;13(1):11-23
Fibrinolytic for treatment of intraventricular hemorrhage: A meta-analysis and systematic review
Baker AD, Rivera Perla KM, Yu Z, Dlugash R, Avadhani R, Mould WA, Ziai W, Thompson RE, Staykov D, Hanley DF

Read Article

Neurology. 2017 Oct 10;89(15):1553-1560
CSF inflammatory response after intraventricular hemorrhage
Fam MD, Zeineddine HA, Eliyas JK, Stadnik A, Jesselson M, McBee N, Lane K, Cao Y, Wu M, Zhang L, Thompson RE, John S, Ziai W, Hanley DF, Awad IA; CLEAR III Trial Investigators

Read Article

J Magn Reson Imaging. 2017 Aug 9
Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage
Zeineddine HA, Girard R, Cao Y, Hobson N, Fam MD, Stadnik A, Tan H, Shen J, Chaudagar K, Shenkar R, Thompson RE, McBee N, Hanley D, Carroll T, Christoforidis GA, Awad IA

Read Article

Joomla3 Appliance - Powered by TurnKey Linux